
AOD-9604
Human Growth Hormone Fragment 176-191
AOD-9604 is a modified fragment of human growth hormone (HGH) comprising amino acids 176-191 from the C-terminus. Developed by Metabolic Pharmaceuticals, this peptide specifically targets fat loss without the growth-promoting effects of full HGH. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation), making it a targeted approach for body composition improvement and weight management.
Complete Dosing Guide
Quick Reference
Administration Method
Subcutaneous injection, typically daily
Step-by-Step Dosing Protocol
Dosing Guidelines
Clinical protocols typically begin with 250 mcg daily for the first week to assess tolerance, followed by escalation to 500 mcg daily for weeks 2-4. Optimal efficacy is generally achieved at 1 mg daily, administered as a single subcutaneous injection. Some protocols utilize twice-daily dosing of 500 mcg (morning and evening) for enhanced fat oxidation. Treatment cycles typically range from 8-12 weeks, with some extended protocols lasting up to 6 months. The peptide should be administered on an empty stomach, preferably 30 minutes before exercise for enhanced lipolytic effects.
Most people start with a small dose (250 mcg) for the first week to make sure they tolerate it well. Then they increase to 500 mcg daily for a few weeks. The best results usually come from 1mg per day, given as one shot. Some people split this into two smaller shots (morning and evening) which can work even better. Treatment usually lasts 2-3 months, though some people use it for up to 6 months. For best results, inject it on an empty stomach about 30 minutes before working out.
Mixing & Injection
Subcutaneous injection using insulin syringes (29-31 gauge, 0.5-1.0 mL capacity) into fatty tissue areas including abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy. The lyophilized powder must be reconstituted with bacteriostatic water (1-2 mL depending on desired concentration). Store reconstituted solution under refrigeration and use within 30 days. Administer at consistent times daily, preferably before meals or exercise when growth hormone levels are naturally elevated.
Subcutaneous injection using insulin syringes (29-31 gauge, 0.5-1.0 mL capacity) into fatty tissue areas including abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy. The lyophilized powder must be reconstituted with bacteriostatic water (1-2 mL depending on desired concentration). Store reconstituted solution under refrigeration and use within 30 days. Administer at consistent times daily, preferably before meals or exercise when growth hormone levels are naturally elevated.
Clinical Administration Guidelines
Injection Protocol
- •Subcutaneous injection daily before bed
- •Rotate between abdomen, thigh, upper arm
- •Daily before bed for optimal effects
- •Can be taken with or without food
Monitoring Schedule
- •Weekly weight and body composition measurements
- •Monthly metabolic markers if applicable
- •Quarterly lipid panels
- •Regular vital signs monitoring
Dosage Calculator
Medical Disclaimer
AOD-9604 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Any use should occur only under medical supervision in approved research settings.